Ares Financial Consulting
TARS icon

Ares Financial Consulting’s Tarsus Pharmaceuticals TARS Stock Holding History

Ares Financial Consulting’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-13
Closed -$818 – 1134
2026
Q2 		$818 Buy
+13
New +$831 ﹤0.01% 1034

Other funds holding TARS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ares Financial Consulting's TARS Position: Q3 2026 in Review

Ares Financial Consulting sold out of Tarsus Pharmaceuticals (TARS) in Q3 2026, closing a stake of 13 shares — an estimated $818 sold.

Ares Financial Consulting first reported a position in TARS in Q2 2026 and held it in 1 quarter. The position peaked at $818 in Q2 2026. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • Ares Financial Consulting reported no remaining Tarsus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 13 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $818.
  • Ares Financial Consulting first reported a position in Tarsus Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Tarsus Pharmaceuticals position peaked at $818 in Q2 2026.
  • 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.